279 related articles for article (PubMed ID: 30913220)
1. Meso scale discovery-based assays for the detection of aggregated huntingtin.
Reindl W; Baldo B; Schulz J; Janack I; Lindner I; Kleinschmidt M; Sedaghat Y; Thiede C; Tillack K; Schmidt C; Cardaun I; Schwagarus T; Herrmann F; Hotze M; Osborne GF; Herrmann S; Weiss A; Zerbinatti C; Bates GP; Bard J; Munoz-Sanjuan I; Macdonald D
PLoS One; 2019; 14(3):e0213521. PubMed ID: 30913220
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates.
Herrmann F; Hessmann M; Schaertl S; Berg-Rosseburg K; Brown CJ; Bursow G; Chiki A; Ebneth A; Gehrmann M; Hoeschen N; Hotze M; Jahn S; Johnson PD; Khetarpal V; Kiselyov A; Kottig K; Ladewig S; Lashuel H; Letschert S; Mills MR; Petersen K; Prime ME; Scheich C; Schmiedel G; Wityak J; Liu L; Dominguez C; Muñoz-Sanjuán I; Bard JA
Sci Rep; 2021 Sep; 11(1):17977. PubMed ID: 34504195
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal Biochemical Assay Analysis of Mutant Huntingtin Exon 1 Protein in R6/2 Mice.
Morozko EL; Ochaba J; Hernandez SJ; Lau A; Sanchez I; Orellana I; Kopan L; Crapser J; Duong JH; Overman J; Yeung S; Steffan JS; Reidling J; Thompson LM
J Huntingtons Dis; 2018; 7(4):321-335. PubMed ID: 30452420
[TBL] [Abstract][Full Text] [Related]
4. Development of mAb-based polyglutamine-dependent and polyglutamine length-independent huntingtin quantification assays with cross-site validation.
Fischer DF; Dijkstra S; Lo K; Suijker J; Correia ACP; Naud P; Poirier M; Tessari MA; Boogaard I; Flynn G; Visser M; Lamers MBAC; McAllister G; Munoz-Sanjuan I; Macdonald D
PLoS One; 2022; 17(4):e0266812. PubMed ID: 35395060
[TBL] [Abstract][Full Text] [Related]
5. Characterization of HTT inclusion size, location, and timing in the zQ175 mouse model of Huntington's disease: an in vivo high-content imaging study.
Carty N; Berson N; Tillack K; Thiede C; Scholz D; Kottig K; Sedaghat Y; Gabrysiak C; Yohrling G; von der Kammer H; Ebneth A; Mack V; Munoz-Sanjuan I; Kwak S
PLoS One; 2015; 10(4):e0123527. PubMed ID: 25859666
[TBL] [Abstract][Full Text] [Related]
6. Amplification of neurotoxic HTTex1 assemblies in human neurons.
Chongtham A; Isas JM; Pandey NK; Rawat A; Yoo JH; Mastro T; Kennedy MB; Langen R; Khoshnan A
Neurobiol Dis; 2021 Nov; 159():105517. PubMed ID: 34563643
[TBL] [Abstract][Full Text] [Related]
7. Site-specific ubiquitination of pathogenic huntingtin attenuates its deleterious effects.
Hakim-Eshed V; Boulos A; Cohen-Rosenzweig C; Yu-Taeger L; Ziv T; Kwon YT; Riess O; Phuc Nguyen HH; Ziv NE; Ciechanover A
Proc Natl Acad Sci U S A; 2020 Aug; 117(31):18661-18669. PubMed ID: 32675242
[TBL] [Abstract][Full Text] [Related]
8. N-terminal mutant huntingtin deposition correlates with CAG repeat length and symptom onset, but not neuronal loss in Huntington's disease.
Layburn FE; Tan AYS; Mehrabi NF; Curtis MA; Tippett LJ; Turner CP; Riguet N; Aeschbach L; Lashuel HA; Dragunow M; Faull RLM; Singh-Bains MK
Neurobiol Dis; 2022 Nov; 174():105884. PubMed ID: 36220612
[TBL] [Abstract][Full Text] [Related]
9. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice.
Gray M; Shirasaki DI; Cepeda C; André VM; Wilburn B; Lu XH; Tao J; Yamazaki I; Li SH; Sun YE; Li XJ; Levine MS; Yang XW
J Neurosci; 2008 Jun; 28(24):6182-95. PubMed ID: 18550760
[TBL] [Abstract][Full Text] [Related]
10. Bioinformatics analysis of Ras homologue enriched in the striatum, a potential target for Huntington's disease therapy.
Carbo M; Brandi V; Pascarella G; Staid DS; Colotti G; Polticelli F; Ilari A; Morea V
Int J Mol Med; 2019 Dec; 44(6):2223-2233. PubMed ID: 31638189
[TBL] [Abstract][Full Text] [Related]
11. Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease.
Caron NS; Banos R; Yanick C; Aly AE; Byrne LM; Smith ED; Xie Y; Smith SEP; Potluri N; Findlay Black H; Casal L; Ko S; Cheung D; Kim H; Seong IS; Wild EJ; Song JJ; Hayden MR; Southwell AL
J Neurosci; 2021 Jan; 41(4):780-796. PubMed ID: 33310753
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid mutant huntingtin is a biomarker for huntingtin lowering in the striatum of Huntington disease mice.
Caron NS; Banos R; Aly AE; Xie Y; Ko S; Potluri N; Anderson C; Black HF; Anderson LM; Gordon B; Southwell AL; Hayden MR
Neurobiol Dis; 2022 May; 166():105652. PubMed ID: 35143966
[TBL] [Abstract][Full Text] [Related]
13. Analysis of mutant and total huntingtin expression in Huntington's disease murine models.
Fodale V; Pintauro R; Daldin M; Altobelli R; Spiezia MC; Bisbocci M; Macdonald D; Bresciani A
Sci Rep; 2020 Dec; 10(1):22137. PubMed ID: 33335120
[TBL] [Abstract][Full Text] [Related]
14. Effects of flanking sequences and cellular context on subcellular behavior and pathology of mutant HTT.
Chongtham A; Bornemann DJ; Barbaro BA; Lukacsovich T; Agrawal N; Syed A; Worthge S; Purcell J; Burke J; Chin TM; Marsh JL
Hum Mol Genet; 2020 Mar; 29(4):674-688. PubMed ID: 31943010
[TBL] [Abstract][Full Text] [Related]
15. A series of N-terminal epitope tagged Hdh knock-in alleles expressing normal and mutant huntingtin: their application to understanding the effect of increasing the length of normal Huntingtin's polyglutamine stretch on CAG140 mouse model pathogenesis.
Zheng S; Ghitani N; Blackburn JS; Liu JP; Zeitlin SO
Mol Brain; 2012 Aug; 5():28. PubMed ID: 22892315
[TBL] [Abstract][Full Text] [Related]
16. Exploding the Repeat Length Paradigm while Exploring Amyloid Toxicity in Huntington's Disease.
Wetzel R
Acc Chem Res; 2020 Oct; 53(10):2347-2357. PubMed ID: 32975927
[TBL] [Abstract][Full Text] [Related]
17. Development of a ligand for in vivo imaging of mutant huntingtin in Huntington's disease.
Bertoglio D; Bard J; Hessmann M; Liu L; Gärtner A; De Lombaerde S; Huscher B; Zajicek F; Miranda A; Peters F; Herrmann F; Schaertl S; Vasilkovska T; Brown CJ; Johnson PD; Prime ME; Mills MR; Van der Linden A; Mrzljak L; Khetarpal V; Wang Y; Marchionini DM; Skinbjerg M; Verhaeghe J; Dominguez C; Staelens S; Munoz-Sanjuan I
Sci Transl Med; 2022 Feb; 14(630):eabm3682. PubMed ID: 35108063
[TBL] [Abstract][Full Text] [Related]
18. Huntingtin affinity for partners is not changed by polyglutamine length: aggregation itself triggers aberrant interactions.
Davranche A; Aviolat H; Zeder-Lutz G; Busso D; Altschuh D; Trottier Y; Klein FA
Hum Mol Genet; 2011 Jul; 20(14):2795-806. PubMed ID: 21518730
[TBL] [Abstract][Full Text] [Related]
19. Modulation of mutant Huntingtin aggregates and toxicity by human myeloid leukemia factors.
Banerjee M; Datta M; Bhattacharyya NP
Int J Biochem Cell Biol; 2017 Jan; 82():1-9. PubMed ID: 27840155
[TBL] [Abstract][Full Text] [Related]
20. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice.
Garriga-Canut M; Agustín-Pavón C; Herrmann F; Sánchez A; Dierssen M; Fillat C; Isalan M
Proc Natl Acad Sci U S A; 2012 Nov; 109(45):E3136-45. PubMed ID: 23054839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
